Relationship between TIGIT expression on T cells and the prognosis of patients with hepatocellular carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Relationship between TIGIT expression on T cells and the prognosis of patients with hepatocellular carcinoma

Published:2024-09-09 Issue:1 Volume:24 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Guo Yuan,Yang Xiong,Xia Wei Li,Zhu Wen Bo,Li Fang Ting,Hu Hong Tao,Li Hai Liang

Funder

Medical Education Research Project of Henan Province

Henan Province Natural Science Foundation

Technology Major Project of the Ministry of Science and Technology of China

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s12885-024-12876-5.pdf

Reference25 articles.

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.

2. Jin ZC, Zhong BY, Chen JJ, Zhu HD, Sun JH, Yin GW, et al. Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study. Eur Radiol. 2023;33:8669–81.

3. Duan X, Li H, Kuang D, Chen P, Zhang K, Li Y, et al. Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study. Hepatol Int. 2023;17:915–26.

4. Ju S, Zhou C, Yang C, Wang C, Liu J, Wang Y, et al. Apatinib plus camrelizumab with/without chemoembolization for hepatocellular carcinoma: a real-world experience of a single center. Front Oncol. 2022;11:835889.

5. Zhang C, Wang Y, Xun X, Wang S, Xiang X, Hu S, et al. TIGIT can exert immunosuppressive effects on CD8 + T cells by the CD155/TIGIT signaling pathway for hepatocellular carcinoma in vitro. J Immunother. 2020;43:236–43.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3